Ownership history in Frazier Life Sciences Management, L.P. · 13 quarters on record
This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in NEWAMSTERDAM PHARMA COMPANY (NAMS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 16,943,774 | +241,818 | +1.4% | 15.96% | $594.4M | $35.08 |
| 2025 Q3 | ADDED | 16,701,956 | +94,882 | +0.6% | 14.23% | $475.0M | $28.44 |
| 2025 Q2 | ADDED | 16,607,074 | +490,656 | +3.0% | 12.03% | $300.8M | $18.11 |
| 2025 Q1 | ADDED | 16,116,418 | +200,000 | +1.3% | 15.08% | $329.9M | $20.47 |
| 2024 Q4 | ADDED | 15,916,418 | +3,061,224 | +23.8% | 16.98% | $409.1M | $25.70 |
| 2024 Q3 | ADDED | 12,855,194 | +628,251 | +5.1% | 8.55% | $213.4M | $16.60 |
| 2024 Q2 | UNCHANGED | 12,226,943 | — | 0% | 10.99% | $234.9M | $19.21 |
| 2024 Q1 | ADDED | 12,226,943 | +95,238 | +0.8% | 12.20% | $289.2M | $23.65 |
| 2023 Q4 | UNCHANGED | 12,131,705 | — | 0% | 7.25% | $135.5M | $11.17 |
| 2023 Q3 | ADDED | 12,131,705 | +1,259,902 | +11.6% | 7.45% | $112.2M | $9.25 |
As of 2025 Q4 — sorted by position size